{
    "clinical_study": {
        "@rank": "95993", 
        "brief_summary": {
            "textblock": "RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver\n      tumor-killing substances to them without harming normal cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy consisting\n      of rituximab in treating patients with refractory or recurrent hairy cell leukemia following\n      cladribine therapy."
        }, 
        "brief_title": "Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy", 
        "completion_date": {
            "#text": "July 2007", 
            "@type": "Actual"
        }, 
        "condition": "Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Hairy Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the rate of complete and partial remission, remission duration, and relapse\n           free survival after treatment with rituximab in patients with refractory or recurrent\n           hairy cell leukemia who previously received cladribine.\n\n        -  Determine the acute and long term toxicity of rituximab in these patients.\n\n      OUTLINE: This is an open-label, multicenter study.\n\n      Patients receive rituximab IV over several hours once a week for 4 weeks.\n\n      Patients are followed every 3 months for 3 years and every 6 months thereafter.\n\n      PROJECTED ACCRUAL: A total of 8-25 patients will be accrued for this study within 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically proven hairy cell leukemia (HCL)\n\n               -  Classic HCL\n\n                    -  Hairy cells in the bone marrow and/or peripheral blood which co-express\n                       CD20/CD25 or CD20/CD11c, and/or which are positive for tartrate resistant\n                       acid phophatase (TRAP)\n\n               -  Prolymphocytic HCL variant\n\n                    -  Lymphoid cells in the bone marrow and/or peripheral blood with morphology\n                       intermediate between typical hairy cells and prolymphocytes, which\n                       co-express CD20/CD11c but lack CD25 expression, and which are negative for\n                       TRAP\n\n          -  Progressive or recurrent disease after prior treatment with cladribine\n\n               -  Greater than 1 month since standard dose cladribine OR\n\n               -  Greater than 3 months since low dose cladribine\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  WHO 0-2\n\n        Life expectancy:\n\n          -  At least 3 months\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Bilirubin no greater than 2.0 mg/dL\n\n        Renal:\n\n          -  Creatinine no greater than 2.3 mg/dL\n\n        Cardiovascular:\n\n          -  No serious cardiac disease\n\n        Other:\n\n          -  No acute or chronic infection\n\n          -  HIV negative\n\n          -  No psychosis\n\n          -  Not pregnant or nursing\n\n          -  No other prior or concurrent malignancy except carcinoma in situ of the cervix or\n             basal cell or squamous cell skin cancer\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  Recovered from prior chemotherapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  Not specified\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  Recovered from prior therapy\n\n          -  No concurrent cytoreductive therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003757", 
            "org_study_id": "SAKK 31/98", 
            "secondary_id": [
                "SWS-SAKK-31/98", 
                "EU-98073"
            ]
        }, 
        "intervention": {
            "intervention_name": "rituximab", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Rituximab", 
                "Cladribine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "progressive hairy cell leukemia, initial treatment", 
            "refractory hairy cell leukemia"
        ], 
        "lastchanged_date": "May 14, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "zip": "CH-8008"
                }, 
                "name": "Klinik Hirslanden"
            }
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "official_title": "Rituximab (IDEC-C2B8, Mabthera) in Patients With Hairy Cell Leukemia Relapsing After Treatment With 2-Chlorodeoxyadenosine (CDA)", 
        "overall_official": {
            "affiliation": "Klinik Hirslanden", 
            "last_name": "Albert von Rohr, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2002", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003757"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "18603561", 
            "citation": "Zenh\u00e4usern R, Simcock M, Gratwohl A, Hess U, Bargetzi M, Tobler A; Swiss Group for Clinical Cancer Research (SAKK). Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98). Haematologica. 2008 Sep;93(9):1426-8. Epub 2008 Jul 4."
        }, 
        "source": "Swiss Group for Clinical Cancer Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Swiss Group for Clinical Cancer Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 1998", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }, 
    "geocoordinates": {
        "Klinik Hirslanden": "47.369 8.539"
    }
}